Universal LC-MS method for minimized carryover in a discovery bioanalytical setting

Bioanalysis

Volumn 4, Issue 9, 2012, Pages 1025-1037

  Williams, John S ^a   Donahue, Stephanie H ^a   Gao, Hong ^a   Brummel, Christopher L ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXAPINE; CORYNANTHINE; DESIPRAMINE; DILAZEP; DILTIAZEM; DIMETHYL SULFOXIDE; DROPERIDOL; KETOCONAZOLE; KETOTIFEN; LOPERAMIDE; MELATONIN; NOSCAPINE; PALMATINE; PROPRANOLOL; SULFATHIAZOLE; TRIMETHOPRIM; VERAPAMIL; YOHIMBINE;

ACCURACY; ANALYTIC METHOD; CARRYOVER; CHEMICAL ANALYSIS; COLUMN CHROMATOGRAPHY; COMPARATIVE EFFECTIVENESS; CONTAMINATION; CONTROLLED STUDY; DRUG RESEARCH; ELUTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PARTICLE SIZE; PERFORMANCE; PROCESS OPTIMIZATION; RESIDUE ANALYSIS; REVIEW; SAMPLER; SAW TOOTH WASH;

ANIMALS; AUTOMATION; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; MASS SPECTROMETRY; PHARMACEUTICAL PREPARATIONS; PLASMA; QUALITY CONTROL; RATS;

EID: 84861349591     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.12.76     Document Type: Review

References (16)

1. Lee MS, Kerns EH. LC-MS applications in drug development. Mass Spectrum. Rev. 18(3-4), 187-279 (1999).
2. Hopfgartner G, Bourgogne E. Quantitative high-throughput analysis of drugs in biological matrices by mass spectrometry. Mass Spectrum. Rev. 22(3), 195-214 (2003).
3. Bansal S, Destefano A. Key elements of bioanalytical method validation for small molecules. AAPS J. 9(1), E109-E114 (2007).
4. Viswanathan CT, Bansal S, Booth B et al. Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays. Pharm. Res. 24(10), 1962-1973 (2007).
5. Zeng W, Musson DG, Fisher AL, Wang AQ. A new approach for evaluating carryover and its influence on quantitation in high-performance liquid chromatography and tandem mass spectrometry assay. Rapid Commun. Mass Spectrom. 20(4), 635-640 (2006).
6. Clouser-Roche A, Johnson K, Fast D, Tang D. Beyond pass/fail: A procedure for evaluating the effect of carryover in bioanalytical LC-MS/MS methods. J. Pharm. Biomed. Anal. 47(1), 146-155 (2008).
7. Hughes NC, Wong EY, Fan J, Bajaj N. Determination of carryover and contamination for mass spectrometry-based chromatographic assays. AAPS J. 9(3), E353-E360 (2007).
8. Dolan JW. Autosampler carryover. LCGC 19(2), 164-168 (2001
9. Yang L, Mann TD, Little D, Wu N, Clement RP, Rudewicz PJ. Evaluation of a four-channel multiplexed electrospray triple quadrupole mass spectrometer for the simultaneous validation of LC-MS/MS methods in four different preclinical matrixes. Anal. Chem. 73(8), 1740-1747 (2001).
10. Dunn-Meynell KW, Wainhaus S, Korfmacher WA. Optimizing an ultrafast generic high-performance liquid chromatography-tandem mass spectrometry method for faster discovery pharmacokinetic sample throughput. Rapid Commun. Mass Spectrom. 19(20), 2905-2910 (2005).
11. Williams S. Ghost peaks in reversed-phase gradient HPLC: A review and update. J. Chromatogr. A 1052(1-2), 1-11 (2004).
12. Mitulovic G, Stingl C, Steinmacher I et al. Preventing carryover of peptides and proteins in nano LC-MS separations. Anal. Chem. 81(14), 5955-5960 (2009).
13. Deagon N, Samuels T, Siburn M. An assessment of autosampler carryover through the determination of ketoconazole in rat plasma by LC-MS/MS. Presented at: 2006 AAPS Annual Meeting and Exposition. TX, USA, 30 October-1 November 2006.
14. Drexler DM, Edinger KJ, Mongillo JJ. Improvements to the sample manipulation design of a LEAP CTC Analytics HTS PAL autosampler used for high-throughput qualitative and quantitative liquid chromatography-mass spectrometry assays JALA 12(3), 152-156 (2007).
15. Shirota O, Mibayashi K, Naruse Y, Mita M. Reduced carryover using an LC autosampler system. American Laboratory 41(11), 11-13 (2009).
16. Wainhaus S, Nardo C, Anstatt R, Wang S, Dunn-Meynell K, Korfmacher W. Ultra fast liquid chromatography-MS/MS for pharmacokinetic and metabolic profiling within drug discovery. Int. Drug Discov. 2(1), 6-12 (2007